278 related articles for article (PubMed ID: 28396525)
1. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.
Allen E; Missiaen R; Bergers G
Cold Spring Harb Symp Quant Biol; 2016; 81():21-29. PubMed ID: 28396525
[TBL] [Abstract][Full Text] [Related]
2. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective.
Rivera L; Pandika M; Bergers G
Adv Exp Med Biol; 2014; 772():83-99. PubMed ID: 24272355
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
[TBL] [Abstract][Full Text] [Related]
4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
6. VEGF signaling in cancer treatment.
Sia D; Alsinet C; Newell P; Villanueva A
Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
[TBL] [Abstract][Full Text] [Related]
7. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
10. VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P
Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
[TBL] [Abstract][Full Text] [Related]
11. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
13. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Rosen LS
Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy and tumor progression.
Blagosklonny MV
Cancer Cell; 2004 Jan; 5(1):13-7. PubMed ID: 14749122
[TBL] [Abstract][Full Text] [Related]
17. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
Simon T; Gagliano T; Giamas G
Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin B inhibits tumor angiogenesis by triggering the mitochondrial signaling pathway in endothelial cells.
Piao XM; Gao F; Zhu JX; Wang LJ; Zhao X; Li X; Sheng MM; Zhang Y
Int J Mol Med; 2018 Aug; 42(2):1018-1025. PubMed ID: 29717773
[TBL] [Abstract][Full Text] [Related]
19. Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis.
Song K; Wu H; Rahman HN; Dong Y; Wen A; Brophy ML; Wong S; Kwak S; Bielenberg DR; Chen H
Cell Mol Life Sci; 2017 Feb; 74(3):393-398. PubMed ID: 27572288
[TBL] [Abstract][Full Text] [Related]
20. Controlling escape from angiogenesis inhibitors.
Sennino B; McDonald DM
Nat Rev Cancer; 2012 Oct; 12(10):699-709. PubMed ID: 23001349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
